Mounjaro, Zepbound cut odds for diabetes by 94% in at-risk people, study findsMounjaro, Zepbound cut odds for diabetes by 94% in at-risk people, study finds
Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes by 94%, a new trial shows. Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person Read More
Disproportionality Analysis From WHO Data on Semaglutide, Liraglutide, and SuicidalityDisproportionality Analysis From WHO Data on Semaglutide, Liraglutide, and Suicidality
This case control study evaluates potential signals for suicidal and self-injurious adverse drug reactions associated with semaglutide and liraglutide. This case control study evaluates potential signals for suicidal and self-injurious adverse drug reactions associated with semaglutide and liraglutide.
GLP-1 Receptor Agonists and SuicidalityGLP-1 Receptor Agonists and Suicidality
Psychiatry Psychiatry
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Type 2 DiabetesClinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Type 2 Diabetes
This cohort study investigates the risks of mortality and adverse cardiovascular and kidney outcomes among individuals with type 2 diabetes taking tirzepatide vs glucagon-like peptide 1 receptor agonists. This cohort study investigates the risks of mortality and adverse cardiovascular and kidney outcomes among individuals with type 2 diabetes taking tirzepatide vs glucagon-like peptide 1 receptor Read More
Popularity of Ozempic and Wegovy among privately insured patients may worsen disparities, suggests studyPopularity of Ozempic and Wegovy among privately insured patients may worsen disparities, suggests study
A USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with private insurance. A USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less Read More
Prescription Fills for Semaglutide Products by Payment MethodPrescription Fills for Semaglutide Products by Payment Method
This cross-sectional study examines trends in US prescription fills for semaglutide products by payment method between January 2021 and December 2023. This cross-sectional study examines trends in US prescription fills for semaglutide products by payment method between January 2021 and December 2023.
Safety and Risk Assessment of No-Prescription Online Semaglutide PurchasesSafety and Risk Assessment of No-Prescription Online Semaglutide Purchases
This qualitative study assesses the quality, amount of active ingredient, and characteristics associated with counterfeiting of semaglutide purchased from illegal online pharmacies without a prescription. This qualitative study assesses the quality, amount of active ingredient, and characteristics associated with counterfeiting of semaglutide purchased from illegal online pharmacies without a prescription.
Ozempic and Wegovy could help people quit smokingOzempic and Wegovy could help people quit smoking
Semaglutide-based medicines such as Ozempic and Wegovy, which can help people lose weight, may also reduce tobacco cravings Semaglutide-based medicines such as Ozempic and Wegovy, which can help people lose weight, may also reduce tobacco cravings
Study indicates surge in GLP-1RA prescriptions to treat obesity and prevent its complicationsStudy indicates surge in GLP-1RA prescriptions to treat obesity and prevent its complications
Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)—prescription medications sold under popular drug names like Ozempic and Wegovy—in the United States. Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like Read More
Sister hormone of GLP-1 could lead to better weight-loss drugsSister hormone of GLP-1 could lead to better weight-loss drugs
Much like the Cold War space race, the world’s pharmaceutical giants are currently scrambling to produce the best weight-loss drug. They all want to be the first to explore the nooks and crannies of the body in order to be able to design the optimal drug. However, several pharmaceutical giants disagree on what the next Read More